The Economic Value of Ozempic® (Semaglutide) Injection 0.5 mg, 1 mg, or 2 mg in Medicare Beneficiaries

This clinical brief was created and sponsored by Novo Nordisk.

It is intended for payers, formulary committees, or other similar entities
with knowledge and expertise in the area of healthcare economic analysis,
carrying out their responsibilities for the selection of drugs for coverage
or reimbursement.